Published Date:2020-11-11
Original Link:https://www.onenessbio.com/en/news_detail72_1.htm
| No | 1 | Date of announcement | 2020/11/11 | Time of announcement | 18:25:13 |
|---|---|---|---|---|---|
| Subject | Oral presentation by Oneness Biotech at EWMA 2020 virtual conference on ON101 global Phase 3 MRCT results. |
||||
| To which item it meets |
paragraph 12 | Date of events | 2020/11/11 | ||
| Statement | |||||
|
1.Date of institutional investor conference: 2020/11/18
2.Time of institutional investor conference: 16:02 (GMT+8) 3.Location of institutional investor conference:Online Investor Conference 4.Outline of institutional investor conference: (1)Oneness Biotech Co., Ltd. has been accepted for an oral presentation at 30th EWMA conference on 18th Nov., 2020 on Phase III MRCT results of ON101 (new drug for diabetic foot ulcers). (2)The European Wound Management Association (EWMA) was founded in 1991. Every year, EWMA attracts over 3,000 health professional participants from more than 80 countries. The conference of this year will be held virtually due to the global pandemic of COVID-19. 5.Any other matters that need to be specified:The presentation slides will be made publicly by being uploaded to Market Observation Post System according to the regulation. |
|||||